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Cancer genetics: Two tracks but one race?
David Sidransky
The tumor suppressor gene encoding the cyclin-
dependent kinase inhibitor p16 has, remarkably, been
found to encode a second protein, p19, with a distinct
sequence translated from an alternative reading frame;
like p16, p19 can block the cell cycle in G1 phase.
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The protein p16 was initially identified as an inhibitor of
cyclin-dependent kinase (Cdk) activity — specifically, it
was found to bind and inhibit cyclin D–Cdk4 [1]. This
inhibition prevents phosphorylation of the retinoblastoma
product (Rb) and progression from G1 to S phases of the
cell cycle [2,3]. Previous observations that the Rb gene is
frequently inactivated, and the cyclin D gene amplified,
in human cancer cells already pointed to an important role
for these regulators of the G1/S transition in neoplasia.
Like other Cdk inhibitor genes, such as p21, p16 was thus
a candidate tumor suppressor gene, potentially inactivated
in human cancer progression. Subsequent studies have
established that inactivation of p16 plays a major role in
human cancer, and it may be the first mammalian example
of a gene that codes two distinct proteins using over-
lapping reading frames.
As p16 was coming to light, frantic efforts were being
made by several groups to clone a critical tumor suppressor
gene believed to be located on chromosome 9 in a region,
9p21, which is perhaps the most common site of chromo-
somal deletions in human cancer. Part of the minimal
region containing the putative 9p21 tumor suppressor
gene was completely sequenced and found to contain the
recently cloned p16 gene [4]. Point mutations in p16 were
subsequently identified in familial melanoma patients [5],
many types of tumor cell line [4], and some types of
primary cancer [6]. Reintroduction of p16 into tumor cell
lines led to a significant suppression of growth in clono-
genic assays, and to a marked increase in G1/S cell-cycle
arrest [7]. As expected, reintroduction of p16 into Rb–/– cell
lines did not suppress growth, as inactivation of cyclin
D–Cdk4 complexes and inhibition of the cell cycle is
achieved through the downstream effector Rb [8].
Genetic studies initially raised doubts about the impor-
tance of p16 inactivation in primary neoplasia [9,10]. We
[11] and others did eventually find, however, that in most
types of tumor both p16 alleles were deleted; unlike many
other tumor suppressor genes, few examples were found
where p16 was inactivated by point mutations. It was
further found that, in significant number of primary
tumors and cell lines, the ‘CpG island’ upstream of p16
was methylated — a modification previously associated
with complete transcriptional inactivation of the gene [12].
Surprisingly, however, tumors with this DNA methylation
pattern still produced another abundant p16 transcript.
We and others [13,14] cloned this alternative transcript,
and found that it was derived from a second transcriptional
initiation site, more than 18 kilobases (kb) upstream of the
previously defined p16 exon 1 (now called 1a), producing
a new transcript with a distinct first exon (called 1b)
spliced on to the remaining p16 exons, 2 and 3 (Fig. 1). It
was already known that cell lines lacking Rb expressed
high levels of p16, leading to suggestions that p16 might
be part of an inhibitory feedback loop in which Cdk4 inac-
tivation allows accumulation of unphosphorylated Rb,
setting the stage for the next cycle (reviewed in [15]).
Recently, the production of both p16 transcripts, a and b,
has been shown to be significantly increased after inacti-
vation of Rb by simian virus 40 (SV40) T antigen [16].
The cis DNA sequence mediating this effect for p16 a was
mapped to a region ~800–900 base pairs upstream of
exon 1a. Interestingly, exon 1b is further upstream and
Figure 1
Genomic structure of human p16 gene, showing how the a and b
transcripts are transcribed from different initiation sites and encode
proteins with completely different amino-acid sequences. Although the
two transcripts share exon 2 nucleotide sequences, these are
translated in different frames, and translation terminates at different
points in the two cases.
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contains a ‘GT box’ within its own putative promoter
region [13]. The presence of such a separate promoter
sequence for p16 b suggests that its transcription may be
regulated independently of p16 a.
Closer examination of the p16 b transcript revealed that
the novel first exon contains an open reading frame poten-
tially extending into exon 2 of p16. However, all three pos-
sible reading frames were out of frame with the known
coding region of exon 1a that extended through exons 2
and 3. This left open some intriguing possibilities. First,
that the alternative p16 b transcript is completely untrans-
lated. Second, that exons 1a and 1b are both untranslated,
and the third methionine codon in exon 2, which lies
within a possible ribosome entry sequence, initiates the
same truncated protein from both transcripts. And third,
the most interesting possibility, that a novel protein is pro-
duced from one of the putative reading frames starting in
exon 1b. 
With regard to the first possibility, it is notable that the
p16 b transcript is often more abundant than the p16 a
transcript in cell lines [13]. This may reflect a regulatory
role played by p16 at the RNA level, either on itself or on
other, unknown, genes. With regard to the second possi-
bility, in vitro translation of the p16 b transcript did yield
low levels of a 9 kDa protein compatible with translation
from the third methionine codon in exon 2 [13]. However,
immune precipitation with both polyclonal and mono-
clonal antibodies against the carboxyl terminus of p16
failed to recognize this product in cell lines. This still left
open the improbable possibility that p16 is the first mam-
malian example of a gene that encodes distinct proteins
using overlapping reading frames.
Quelle et al. [17] recently cloned the mouse p16 gene and
made polyclonal antibodies against peptides potentially
encoded by the longest of the b reading frames. These
antibodies identified a novel 19 kDa protein in cells,
called p19ARF (Fig. 1), the size of which is compatible
with its translation from this reading frame. Reintroduc-
tion of p19ARF into p16–/– mutant NIH3T3 cells pro-
duced marked growth inhibition [17], characterized by
G1/S arrest similar to that caused by p16, and also a signifi-
cant delay in G2/M. Overexpression of cyclin D was found
to overcome the p19ARF-induced G1 block. As expected,
given that its sequence shows no similarity to that of p16,
there were no indications that p19ARF interacts with
cyclin–Cdk complexes. This striking observation implies
that one cell-cycle inhibitor is derived from an alternative
reading frame overlapping that encoding another critical
cell-cycle regulator. 
An immediate question arises as to the nature of the p16 b
product in humans. Although exon 1a is conserved across
most species, exon 1b is poorly conserved [18]. Moreover,
the same reading frame of the human gene would produce a
significantly shorter protein product, because of a prema-
ture termination codon. Although such ‘frame-shifting’ is
well known in viral systems, it has not been previously
observed in higher organisms [19]. With the luxury of a far
greater genome size, it is difficult to understand why the
same sequence would be used to generate distinct proteins.
The possibility of a mutation or deletion knocking out both
of two critical genes is much higher if their sequences
overlap. In human tumors, the entire p16-containing region
is often deleted, so could nature’s experiment in frugality
have generated an Achilles' heel for neoplasia?
Cancer genetics does not lend strong support to this
premise. Quelle et al. [17] point out that previously over-
looked point mutations in exon 2 of p16, which do not
change the sequence of the a product, could lead to sig-
nificant alterations of the b product. Furthermore,
although the entire p16 gene is deleted in many tumors, a
single mutation in exon 2 could inactivate both proteins.
But sequence analysis of 50 tumors with an intact p16 a
coding capacity revealed no alterations of exon 1b [13].
Moreover, in tumors showing methylation upstream of
p16, only a expression is inactivated — b is still an abun-
dant transcript in these tumor cells. These observations
strongly argue that p16 b is not a primary tumorigenic
target. I know of only two examples where small deletions
knock out only exon 1b of p16, one a glioma xenograft [20]
and the other a melanoma cell line [21]. However,
although p16 a is expressed in these two cases, it is
unclear if its normal regulation is intact. Moreover, in both
cases the p15 gene, which encodes another cell-cycle
inhibitor, is also deleted [22].
What about functional studies? My own group’s unpub-
lished observations strongly support a suppressor role for
human p16 b. We have found that reintroduction of p16 b
in cell lines with wild-type or deleted p16 results in
marked growth inhibition, associated with a G1/S arrest,
and a significant decrease in clonogenic assays. Interest-
ingly, this suppression is even seen when constitutively
overexpressed p16 b is introduced into cell lines in which
methylation of p16 blocks expression of the a, but not the
b, product. Furthermore, p16 b may suppress growth of
cell lines lacking Rb. If confirmed, this would suggest that
the p16 b product has a role either downstream of Rb or on
a distinct pathway that also converges on the G1/S check-
point. It may be relevant that Quelle et al. [17] saw
increased p19ARF levels in mouse cell lines with p53 inac-
tivation [17]. It will be of great interest to see if the puta-
tive human p16 b protein can be identified in vivo using
antibodies; at present the possibility remains that negative
cell-cycle regulation is mediated by the b transcripts.
Is p16 b running the same race as p16 a, but on a different
track? Is it an innocent bystander in cancer, ripped out of
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the genome in neoplastic cells when p16 a is inactivated,
or is it also a primary target of tumorigenic mutations?
These and other questions will undoubtedly keep us busy
for a long time to come. 
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